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Abstract
Objectives: One	 important	 group	 of	 people	 at	 higher	 risk	 from	 the	 SARS-	CoV-	
2(COVID-	19)	pandemic	are	those	with	autoimmune	conditions	including	rheumatoid	
arthritis/inflammatory bowel disease. To minimise infection risk, many people have 
been switched from intravenous to subcutaneous biologics including biosimilars.
Design: The survey was designed to understand comparative economic issues re-
lated to the intravenous infusion vs subcutaneous biologic administration routes for 
infliximab.	The	survey	focused	on	direct	cost	drivers/indirect	cost	drivers.	Acquisition	
costs of medicines were not included due to data not being available publicly. Wider 
policy implications linked to the pandemic were also explored.
Setting/participants: Semistructured single telephone interviews were carried out 
with	twenty	key	stakeholders	across	the	National	Health	Service(NHS)	from	35	clini-
cal/42 pharmacy/28 commissioning roles. The interviews were undertaken virtually 
during	April	2020.	From	interview	(n	=	20)	results,	a	simple	cost	analysis	was	devel-
oped	plus	a	qualitative	analysis	of	reports	on	wider	policy/patient	impacts.
Results: Key findings included evidence of significant variation in local infusion tariffs 
UK wide, with interviewees reporting that not all actual costs incurred are captured 
in	published	tariff	costs.	A	cost	analysis	showed	administration	costs	50%	lower	in	
the subcutaneous compared to infusion routes, with most patients administering 
subcutaneous medicines themselves. Other indirect benefits to this route included 
less	pressure	on	infusion	unit	waiting	times/reduced	risk	of	COVID-	19	infection	plus	
reduced patient ‘out of pocket’ costs. However, this was to some extent offset by 
increased	pressure	on	home-	care	and	community/primary	care	services.




tion appears to be the more cost saving option for many patients even without the 
benefit	of	industry	funded	home-	care.
This	is	an	open	access	article	under	the	terms	of	the	Creative	Commons	Attribution-NonCommercial	License,	which	permits	use,	distribution	and	reproduction	
in any medium, provided the original work is properly cited and is not used for commercial purposes.
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1  | BACKGROUND
One	 important	 group	 of	 people	 at	 high	 risk	 in	 SARS-	CoV-	2	
(COVID-	19)	 pandemic	 are	 those	 with	 autoimmune	 conditions,	 in-
cluding those with rheumatoid arthritis and inflammatory bowel dis-
ease.	This	 risk	 is	difficult	 to	quantify	precisely	but	 is	based	on	the	
premise that patients with a connective tissue disorder would, by 
the nature of their condition / treatment and associated immune sta-
tus, be more at risk of becoming seriously unwell after a Coronavirus 
infection.
Depending on the complexity of their condition some of the pa-
tients in this group may be receiving intravenous biologic infusion 
therapy which under normal circumstances is usually administered 
within a hospital or day hospital setting. Prior to the onset of the 
pandemic, there was a policy of maintaining patients in the commu-
nity on subcutaneous biologics as part of a “care closer to home” 
approach.1 However, a significant number of patients have been 
managed with intravenous biologics infusion either due to patient 
clinical status or through patient choice, with some preferring the 
psychological reassurance of an infusion treatment.
With the ongoing pandemic, infusion units have represented 
a potential increased risk to patients receiving biologic infusions 
due	 to	 greater	 (at	 least	 theoretical)	 likelihood	 of	 exposure	 to	 the	
COVID-	19	 virus	 in	 a	 hospital	 setting.	 This	 has	 led	 to	 the	 need	 to	
achieve a careful balance between minimising exposure to infection 
(which	is	likely	to	be	higher	in	a	hospital	setting)	versus	ensuring	that	
the disease is kept under control.2 Even when the risk of hospital 
acquired	 COVID-	19	 infection	 diminishes,3 this is still likely to be 
higher than remaining in the home setting. The National Institute for 
Health	and	Care	Excellence	(NICE)	has	published	guidance	to	ensure	
that patients having intravenous treatment are assessed for possi-
ble switching to the same treatment in subcutaneous form.4 This is 
consistent with local and regional advice to switch from infusion to 
subcutaneous,	home-	based	biologics	administration.5 The approach 
provides an opportunity in the short to intermediate term to avoid 
hospital procedures and manage patients only in a community and/
or home environment where infection risk is likely to be lower.
For this switching approach to be sustainable over the longer 
postpandemic period, there needs to be not only further clinical data 
on switching implications but also economic data to determine the 
comparative cost and wider resource implications between the two 
routes of administration. This is particularly important where, for ex-
ample,	the	National	Health	Service	(NHS)	Trusts	and	commissioners	
in England have been asked to move temporarily away from Payment 
by	Results	to	block	contracts	in	order	to	concentrate	on	Covid-	19.6 
The end of these arrangements will offer an opportunity to review 
contracts and assess the costs and value of switching from infusion 
to	subcutaneous	biologics.	Also,	national	 tariff	 rates	may	not	truly	
represent the administration cost of both intravenous and subcuta-
neous biologics, with this survey providing an opportunity to clarify 
the likely actual costs for each of the modes of administration.
A	subcutaneous	formulation	of	infliximab	received	marketing	au-
thorisation	from	the	European	Medicines	Agency	(EMA)	in	2019	and	
is currently available in Europe for the treatment of rheumatoid ar-
thritis. Infliximab is used to treat a number of autoimmune diseases 
including rheumatoid arthritis, Crohn's disease, ulcerative colitis, an-
kylosing spondylitis, psoriasis, and psoriatic arthritis. The availability 
of infliximab as both an intravenous and subcutaneous preparation 
provides a common reference point for this survey against which 
cost comparisons can be surveyed and evaluated.
The economic costs of medicines can be divided into three cat-
egories: acquisition costs, direct costs and indirect costs.	Acquisition	
costs	are	the	cost	of	acquiring	the	actual	medicine	which	can	vary	
depending, for example, on tender contract pricing. Direct costs are 
the service costs incurred in delivering these medicines, including 
administration costs, healthcare staff, estate, and other resources. 
Service	 activity	 costs	 therefore	 explicitly	 exclude	drug	 acquisition	
costs, that is, refer to administration costs only. Indirect costs in-




This purpose of this study was to provide a comparative analysis 
of the cost of biologics infusion and subcutaneous administration, 
assuming	equivalence	of	efficacy	for	patients	who	are	clinically	ap-
propriate for switching between routes.7	A	key	component	of	 this	
analysis included the role of national tariff costs as well as direct 
and	indirect	costs	not	included	in	these	tariffs.	Additional	economic	
What's known
• One important group of people at high risk in 
COVID-	19	 pandemic	 are	 those	 with	 autoimmune	
conditions, including those with rheumatoid arthritis 
and inflammatory bowel disease.
• Depending on the complexity of their condition, 
some of the patients in this group may be receiving 
intravenous biologic infusion therapy which under 
normal circumstances is administered within a hospi-
tal or day hospital setting.
• The National Institute for Health and Care Excellence 
has published new guidance to ensure that patients 
having intravenous treatment are assessed for possible 
switching to the same treatment in subcutaneous form.
What’s new
•	 A	cost	analysis	showed	that	administration	costs	for	
subcutananous	 routes	are	50%	 lower	 than	 for	 infu-
sion routes, with most patients administering subcu-
taneous medicines themselves.
• Other indirect benefits to this route included less pres-
sure on infusion unit waiting times and reduced risk of 
COVID-	19	infection,	along	with	reduced	patient	costs.
• Cost savings were partly offset by increased pressure 
on	home-	care	and	community/primary	care	services.
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drivers were also considered including infusion unit capacity costs, 
individual	 costs	 to	 patients	 and	potential	 co-	morbidity	 costs	 from	
COVID-	19	infection.	Please	note	that	acquisition	costs	of	medicines	
were not included as the data for these for this class of medicines are 
not routinely available publicly and tend to differ from list prices due 
to local purchasing agreements.
2  | METHODS
2.1 | NHS reference costs of infliximab
For direct administration costs, the NHS regularly produces “refer-
ence cost” data which provides a benchmark against which overall 
service costs can be identified and modelled.8	At	a	 local	 level,	 the	
translation of a service activity into a cost statement is undertaken 
through a coding process. Which code is allocated to a particular 
activity will therefore determine the formal “tariff” for that medicine 
or procedure.
Where the parameters for allocating a service activity to a 
specific code are not clear, cost variation between providers and 
localities can occur, sometime across a wide range.9 The cost of bio-
logic infusion is an example of a service activity that does not have 
a	 specific	 unique	 tariff	 as	 defined	 by	 the	National	 Tariff	 Payment	
System.10 Instead, this service activity is normally identified under 
the class of ‘parenteral chemotherapies’ of which more than one re-
lates	to	infusional	treatments	(Table	1).
For other medicines and procedures, such as subcutaneous ad-
ministration in the community, no clear reference costs exist and 
there is no formal tariff. The risk of no formal tariff being identi-
fied is that the actual costs of an activity can be obscured, meaning 
services are potentially under costed, and, by implication, under-
funded	in	the	 longer	term.	For	biologics,	many	home-	administered	
programmes are funded by medicines manufacturers through home 
care schemes, which can include medicine delivery as well as clinical 
teams to train patients to administer their medications and to review 
them on a regular basis.11 In some areas, these schemes are provided 
and funded by the NHS rather than industry.
In order to establish a baseline of biologics administration cost-
ings, semistructured interviews were carried out with 20 key stake-
holders across the NHS with clinical, pharmacist and commissioning 
roles related to biologics administration for rheumatoid arthritis and 
inflammatory	bowel	disease.	An	initial	105	stakeholders	across	the	
regions of the UK were invited to express interest by email to take 
part	 in	the	study	(35	 in	clinical/42	 in	pharmacy/28	in	comissioning	
roles).	Stakeholders	were	selected	to	be	representative	of	prescrib-
ers,	pharmacists	and	commissioners	across	the	United	Kingdom.	All	
those who responded with an expression of interest (n =	20)	were	
interviewed.
The	survey	was	undertaken	between	5	April	and	27	April	2020.	
The survey was designed to understand the actual estimated costs 
of each route of biologic administration using infliximab as the 
reference medicine. Interviewees were recruited from a pool of 
stakeholders to balance geographical as well as professional role 
representation. Interviewees responded from England, Wales, 
Scotland but not Northern Ireland. The breakdown of professional 
roles interviewed is shown in Figure 1.
The interviews were carried out by telephone using a semistruc-
tured	interview	method	focusing	on	a	key	question	set	as	shown	in	
Figure 2. Questions between the infusion and subcutaneous groups 
were	equivalent	except	for	 items	that	were	unique	to	one	method	
of	administration	only.	The	question	set	was	determined	using	cate-
gories based on standard modelling for medicines economic impact.
From interview (n =	20)	results,	a	simple	comparative	analysis	of	
costs	for	each	route	of	administration	(infusion	and	subcutaneous)	
was conducted, along with a collation and summary of comparative 
qualitative	statements	about	impact	on	clinical	practise	and	patient	
experience.
Respondents were asked to estimate costs across both infu-
sion and subcutaneous administration scenarios. The survey also 
included identification of the range of current national tariffs for 
TA B L E  1   Summary of HRG codes relevant to biologics infusion 
(National	Tariff	Payment	System	2019/20)
HRG code HRG name
Tariff 
(£)
SB12Z Deliver Simple Parenteral Chemotherapy at 
First	Attendance
142
SB13Z Deliver more Complex Parenteral 
Chemotherapy	at	First	Attendance
284
SB14Z Deliver Complex Chemotherapy, including 






F I G U R E  1   Breakdown of interviewee by role type
F I G U R E  2  Summary	of	semistructure	interview	key	question	
set
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biologic infusion and reference costs for subcutaneous administra-
tion	(where	available)	to	gain	insight	into	the	level	of	alignment	be-
tween these costs and actual local cost estimates.
2.2 | Patient and public involvement
There was no patient involvement in this study.
3  | RESULTS
3.1 | Reported cost data including tariff and 
nontariff costs
The average tariff value for infusion reported by interviewees was 
£414 which is consistent with the published tariff value for “Complex 
Chemotherapy, including Prolonged Infusional Treatment, at First 
Attendance”	priced	at	£426.12 However, other tariff codes are avail-
able that are less consistent with the reported averages and which 
represent lower coding cost points, including those for first attend-
ance and follow up.13
In	order	to	compare	equivalent	costs,	a	common	treatment	cycle	
of 12 months was used as a benchmark. For biologic infusions with 
infliximab	 as	 the	 reference,	 this	 equates	 to	maintenance	 of	 every	
8 weeks on average, with subcutaneous treatments being given 
every	2	weeks.	The	total	cycles	for	 infusion	were	taken	as	6.5	per	
year,	with	26	per	year	for	subcutaneous	administration.	Costs	were	
divided into initial one- off costs and maintenance	costs.	One-	off	cost	
included, for example, pharmacist medicines management for switch 
programmes	(infusions)	and	nurse	patient	training	time	(subcutane-
ous).	Maintenance	costs	included	ongoing	monitoring	and	adminis-
tration of medicines where clinically appropriate. From the survey 
data, comparative costs were then calculated over an annual cycle.
The initial focus on the analysis was to understand the extent to 
which biologics tariff service activity coding is a reflection of actual 
direct costs. Table 2 shows reported average and range of infusion 
tariffs calculated by dose.
3.2 | Relevant costs and reference costs
The next stage of the analysis was to evaluate firstly whether the 
infusion tariff reflected all relevant costs and secondarily to evaluate 
a	 “reference	 cost”	 for	 community	 or	 home-	based	 subcutaneous	
administration. These individual cost items were reported as sum-
marised in Table 3. Note that hospital and other estate costs were 
excluded from the analysis as these were reported by all interview-
ees to be included in the infusion tariff cost. Other “in tariff” infusion 
costs were included to provide a benchmark against which subcuta-
neous costs could be estimated.
A	number	of	observations	were	made.	Firstly,	there	was	a	wide	
range of costings used for each of the cost items for the individ-
ual	 identified	 service	 activities.	 All	 nursing	 and	 equipment	 costs	
were	considered	to	be	 in-	tariff	 for	 infusions,	although	blood	test-
ing	(which	is	often	uniquely	defined	by	the	disease	area	and	med-
icine	being	administered)	was	excluded	from	tariff	as	were	uplifts	
for wastage. The estimated total infusion administration cost of 
£441 is higher than a previous study of infliximab infusion costs of 
£382 which included indirect costs such as laboratory tests and GP 
visits.14 However, this difference could be accounted for by infla-
tionary and other cost uplift factors in the period since that study 
was	 undertaken.	 The	 NICE	 study	 data	 indicate	 costs	 of	 £167.68	
for infusion and £3.32 for subcutaneous routes of adminstraton.15 
However, in the NICE figures, the cost analysis did not take into ac-
count wider direct and indirect costs, whilst the subcutaneous ad-
ministration cost was based on hospital administration rather than 
on home delivery and administration.
3.3 | Direct and indirect costs
For subcutaneous administration, where no tariff exists, many of the 
cost	items	were	reported	as	equivalent	to,	or	benchmarked	by,	the	in-
fusion cost items. For example, blood tests and pharmacist time were 
costed similarly across both routes of administration. Where the two 
routes differed were in the cost parameters, with nurse time in subcu-
taneous	administration	being	restricted	to	training	the	patient	to	self-	
administer their medication. Nurse time for infusion is largely driven 
by time on the ward and is included in the existing tariff. For blood 
tests, these were usually taken at 12 weeks for subcutaneous routes 
which is a greater interval than infusion routes which were normally 
around 8 weeks and coinciding with the hospital infusion appoint-
ment.	Another	important	difference	to	note	is	that	Value	Added	Tax	
(VAT)	does	not	apply	to	community	administered	medicines	whereas	
this does apply for hospital administered medicines.16,17
When tariff and nontariff costs were calculated together for 









TA B L E  2   Reported average and range 
of biologics infusion tariff by dose and 
annual	cycle	total	(cost	in	£)
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each	route	were	£2867	for	the	infusion	route	and	£1457	for	the	sub-
cutaneous	route	per	annual	cycle,	which	equates	to	 just	over	50%	
of the infusion route costs. For the infusion route, the additional 
nontariff	direct	costs	equated	to	around	7%	over	and	above	in-	tariff	
costs, meaning the tariff is an underestimate of the true costs. The 
overall subcutaneous cost findings are particularly important given 
the rapid move from infusion to subcutaneous routes during the 
pandemic. With established biologics delivered subcutaneously in 
patients' homes or in primary care, the cost is either absorbed by 
home	care	 (which	 in	 turn	 is	usually	pharma	 funded)	or	by	primary	
care. With rapid switching currently these additional “nonprovider” 
costs need to be recognised and budgeted for.
3.4 | Regional variations
Across	Scotland	and	Wales,	 there	 is	no	 tariff	 system	or	purchaser	
/ provider split. The cost of medicines is usually determined by na-
tional pricing agreements, so there is little price variation across 
any of the health boards in Wales and Scotland. This is related to 
either	 the	 HTA	 approval	 process	 through	 the	 Scottish	 Medicines	
Consortium	(SMC)	in	Scotland	or	to	the	national	procurement	pro-
cess	(tender	price)	in	both	Scotland	and	Wales.	The	acquisition	cost	
is therefore the key driver for treatment choice rather than the as-
sociated service activity costs. Northern Ireland was not included in 
this analysis as no stakeholders were interviewed from this region.
TA B L E  3   Reported breakdown of biologics infusion and subcutaneous cost drivers including tariff status excluding estate costs (T = In 
tariff, NT =	Not	in	tariff	for	infusion	activity;	NA	=	Not	applicable;	Av	=	Average)
































eWastage referred to medicines usage only so reported for information only in this table without affecting overall calculation.
fBlood tests do not include blood therapeutic level testing or antibody testing, which was reported to be rare although estimated to be an average 
cost	of	£75	and	may	be	included	in	the	drug	cost	although	limited	to	one	test	per	patient	per	annum.
gCosts that were identified by interviewees as not being included in the official tariff.
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Another	 factor	 here	 is	 community	 location,	with	 reports	 from	
interviewees that healthcare providers in more rural areas may be 
keener to switch to subcutaneous routes than those in urban areas.
Interviewees reported wide regional variations across both appli-
cation of the national tariff price guidance to coding, along with local 
cost variations, indicating that there is a need for clearer guidance 
across both infusion and subcutaneous administration costings and 
tariff code allocations. The wider range of tariff costs for infusion 
from £100 to £1000 could have significant implications for resource 
availability locally for this class of medicines but also implies that the 
perceived cost effectiveness of subcutaneous administration will 
depend to some extent on local infusion cost coding.
3.5 | Comparison of cost- effectiveness items for 
infusion and subcutaneous routes
Subcutaneous administration routes are associated with higher 
home case treatment costs which could escalate with increased 
switching away from infusions. Table 4 summarises the cost items 
for the infusion and subcutaneous routes of administration of bio-
logics using infliximab as the reference.
3.5.1 | Wastage
For infusions wastage of medicines is kept to a minimum based on 
mg/kg	with	dose-	banding,	rounding	(up	or	down)	and	vial	sharing	all	
used to mitigate against drug wastage. The use of set days for each 
clinic also helps to avoid drug wastage. In one hospital the rheamatoid 
arthritis and inflammatory bowel disorder patients share the infusion 
suite so it is possible to coordinate patients on the same drug to avoid 
wastage through vial sharing. Even so wastage varies a lot with esti-
mates	as	high	as	10%	of	vials,	with	an	estimated	average	of	5%.
For subcutaneous administration, treatments in the community 
are	reported	at	similar	 levels	of	0-	10%	with	5%	being	the	average.	
Where wastage does occur, this may be due to patients stopping 
treatment	because	of	side-	effects	and	 lack	of	response	or	storage	
issues	(refrigeration),	although	patients	are	generally	diligent	about	
storage.	Adherence	 to	medication	 is	 not	 usually	 an	 issue	 as	 being	
symptom free or having reduced symptoms with this class of dis-
eases is a compelling driver for the patient.
3.5.2 | Patient	impact
Interviewees all reported likely greater economic cost to patients of 
the infusion route although did not provide a consistent cost estimate 
for this. Of the few studies in the literature exploring cost to patients, 
one identifies significant cost ranges, particularly around hospital 
parking and lost personal time, with total hospital treatment costs for 
patients being up to £400.16 Patient productivity loss is also a factor 
with up to an estimated three working days a year lost through at-
tendance for biologics infusions, at a patient annual salary loss of over 
£300 using national salary average hourly payment calculations.18
3.5.3 | Infusion	capacity	and	productivity
Interviewees reported significant logistical factors such as long waiting 
lists for infusion units in many regions. This can contribute to worsen-
ing of the patient disease status with potential costs linked to relapse. 
For subcutaneous biologics patients, high demand for homecare na-
tionally	due	to	the	pandemic	was	reported	to	be	an	equivalent	resource	
pressure, with many homecare providers struggling to meet demand.
COVID-	19	is	placing	some	restrictions	on	how	some	homecare	
services operate. Switching from infusion to subcutaneous biologics 
may therefore become increasingly challenging although there is a 






pandemic are likely to remain in place in many areas including the shift 
to	community	/	home-	based	drug	administration.	Further	key	implica-
tions of the pandemic reported by interviewees are listed in Figure 3.
4  | DISCUSSION
In	an	analysis	of	direct/indirect	costs,	excluding	medicine	acquisi-
tion costs, subcutaneous administration appears to be the more 
Cost item Infusion Subcutaneous
Annual	direct	cost	of	administration	per	patient £2867 £1459
Impact on demand for infusion units ↑ ↓
Impact on demand for home care services ↓ ↑
Risk	of	co-	morbidities	from	COVID-	19	infection ↑ ↓




TA B L E  4  Comparison	of	cost-	
effectiveness items for infusion and 
subcutaneous routes of administration for 
infliximab
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cost saving option for many patients even without the benefit of 
industry	 funded	home-	care	 (Table	4).	 In	 the	direct	 cost	 category	
we found that the infusion route of administration is twice the 
cost of the subcutaneous route with additional costs such as blood 
tests	 routinely	not	being	 included	 in	 the	national	 tariff	 (Table	3).	
Indirect costs of infusion include treatment waiting lists due to 
the suboptimal capacity of infusion units, along with greater pa-
tient	costs	(travel,	occupational	time	off),	as	well	as	increased	risk	
of	 COVID-	19	 infection	with	 the	 associated	 clinical	 and	 personal	
costs.	Drug	acquisition	costs	were	not	included	in	the	analysis	due	
to lack of publically available data due to local tender contract 
pricing arrangements. However, overall local comparative route 
benefits can be calculated using the findings from this paper along 
with local pricing data.
For subcutaneous administration, where no tariff exists, many 
of	the	cost	 items	were	reported	as	equivalent	 to,	or	benchmarked	
by,	the	infusion	cost	items	(Table	3).15 For example, blood tests and 
pharmacist time were costed similarly across both routes of admin-
istration.	The	two	routes	differed	in	nurse	time	required,	with	nurse	
time in subcutaneous administration being restricted to training the 
patient	to	self-	administer	their	medication.	Nurse	time	for	infusion	
is largely driven by time on the ward and is included in the exist-
ing tariff. For blood tests these were usually taken at 12 weeks for 
subcutaneous routes which is a greater interval than infusion routes 
which were normally around 8 weeks and coinciding with the hospi-
tal infusion appointment.
Another	important	difference	to	note	is	that	VAT	does	not	apply	
to community administered medicines whereas this does apply for 
hospital	administered	medicines	(19).
The	 COVID-	19	 pandemic	 has	 initiated	 a	 significant	 change	 in	
clinical practise for most disorders including the autoimmune con-
ditions. Key factors in this practise change include the imperative to 
keep high risk patients safe whilst maintaining disease control. This 
paper	reports	a	sample	of	key	stakeholders'	views	on	the	nonacqui-
sition costs of infusion and subcutaneous inflximab with the subcu-
taneous route demonstrating more positive economic impact across 
direct and indirect cost categories, including the potential cost of 
COVID-	19	infection.
Whilst there is a concern about increasing pressure on home care 
services,12 and potentially primary care, subcutaneous routes for the 
F I G U R E  3   Summary of key 
implications for patients receiving 
biologics administration following 
pandemic
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administration of biologics may be the more economically sustainable 
option moving forward beyond the pandemic, if key barriers such as 
home care capacity can be solved. Given high ongoing waiting lists for 




a postpandemic NHS although long waiting lists for assessment and 
reviews following pandemic delay are likely to see ongoing higher 
demand for the foreseeable future with associated implications.
4.1 | Strengths and limitations of the study
Our findings are based on a relatively small sample of stakehold-
ers expert in the field of biologics medicine. Nevertheless, they are 
relevant to prescribing of biologic agents as we emerge from the 
COVID-	19	pandemic.
However, the information provided was based on their own per-
sonal knowledge and opinion which reflects local perceptions of 
cost and is therefore not a substitute for an indepth heath econom-
ics study of comparative costs of intraveneous and subcutaneous 
biologics adminstraton.
In addition, wider indirect costs such as impact on infusion units 
and	 risk	of	COVID-	19	 infection	were	not	quantiatively	costed	due	
to	 lack	of	 information	on	frequency	of	occurrence	and	actual	cost	
impact in the group of patients with autoimmune diseases receiving 
biologics through these routes.
Nevertheless, the perceptions of the stakeholders interviewed 
are likely to be a true reflection of how costs are perceived and man-
aged within health economies in England, for intravenous and sub-
cutaneous biologic medicines. These perceptions in turn are likely to 
have a direct impact on medicines choice from a clinical and medi-
cines funding perspective.
The authors acknowledge that our survey does not take into ac-
count longer term real world efficacy comparisons. There is also a 
recognition that there is a subgroup of patients who, due to disease 







costs, subcutaneous administration appears to be the more cost sav-
ing option for many patients even without the benefit of industry 
funded	home-	care.
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